MGMT and cancer: A landmark clinical trial conducted by the European Organization for Research and Treatment of Cancer (EORTC) revealed that the current gold standard of therapy involving RT and TMZ increased the median survival of patients with MGMT promoter methylation by 6.4 months, while median survival did not increase a statistically significant amount for patients that did not exhibit MGMT promoter methylation [8].